Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Regulation

Another setback for implantable GLP-1 as FDA panel cites safety, delivery concerns

Even if ITCA 650 were approved, the diabetes therapy would have a tough commercial road

September 21, 2023 11:47 PM UTC

The road to approval for implantable diabetes therapy ITCA 650 just got longer, after an FDA advisory committee unanimously voted that the therapy’s benefits do not outweigh its risks, at least not without another study. But even if i2O Therapeutics Inc. was able to address the outstanding questions about the therapy’s renal and cardiovascular safety, it is difficult to envision the product successfully competing with the leading GLP-1R agonists on the market.

On Thursday, FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 0-19, with no abstentions, against the risk-benefit profile of ITCA 650 in patients with Type II diabetes. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

I2o Therapeutics Inc.